A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD
A Phase I/II Clinical Study Evaluating the Safety and Efficacy of NCR102 Injection in the Treatment of Acute Graft-versus-Host Disease (aGVHD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yanqiu Li
- Phone Number: 400-888-2032
- Email: yqli@nuwacell.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age>18 years and <70 years old (including threshold), gender not limited;
- Grade II to IV gastrointestinal involvement acute graft-versus-host disease(aGVHD);
- Subjects with Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD);
- Failed to second-line aGVHD treatment;
- Subjects will receive NCR102 injection treatment within 3 days after enrollment;
- Voluntarily sign an informed consent form.
Exclusion Criteria:
- Subjects have lung disease, and investigators have determined that they are not suitable for the study;
- Subjects with severe hepatic vein occlusion disease or sinus vein occlusion syndrome;
- Subjects with signs/symptoms of chronic GVHD;
- Subjects who are clinically assessed by the investigator could not be ruled out as having diarrhea caused by cytomegalovirus (CMV) enteritis, transplant related thrombotic microvascular disease (TA-TMA), or digestive tract infection;
- Eastern Cooperative Oncology Group(ECOG)>3;
- Subjects have other diseases or physiological conditions that may interfere with the evaluation results of this trial, or life-threatening complications;
- Subjects had active malignant solid tumors within the past 5 years;
- Subjects had a known history of severe allergies to blood products, or heterologous proteins.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NCR102 injection
Cohort1:Low dose NCR102 injection; Cohort2:High dose NCR102 injection
|
Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Event(AE) or Serious Adverse Event(SAE)
Time Frame: 100 days after first administration of NCR102 injection
|
Number of participants with treatment-related adverse events or serious adverse events as assessed by CTCAE v5.0
|
100 days after first administration of NCR102 injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ORR at Day 28
Time Frame: 28 days after first dose administration
|
Overall Response Rate(ORR) at Day 28
|
28 days after first dose administration
|
|
CRR at Day 28
Time Frame: 28 days after first dose administration
|
Complete Response Rate(CRR) at Day 28
|
28 days after first dose administration
|
|
ORR at Day 56
Time Frame: 56 days after first dose administration
|
Overall Response Rate(ORR) at Day 56
|
56 days after first dose administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NCR102-1001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.